Status: Recruiting
Study on B7-H3 Targeted Affibody Radioligand Probes for PET Imaging of Solid Tumors
Based on \[68Ga\]B7H3 Affibody-BCH, this study investigates its radioactive uptake and imaging capabilities in tumor patients, with the aim of establishing a correlation between radioactive uptake and B7-H3 receptor expression. Utilizing whole-body PET technology, the pharmacokinetic dynamics of \[68Ga\]B7H3 Affibody-BCH are examined to ascertain its pharmacological characteristics. Ultimately, this research establishes a framework for pharmacokinetic analysis using whole-body PET.
Participants needed: 50
Trial details
Phase: Early Phase 1Age: 18-75Biological sex: AllType: InterventionalSponsor: Peking University Cancer Hospital & InstituteUpdated: Aug 23, 2024Locations: 1
Eligibility criteria
Age range 18-75 years, open to both male and female participants; [+8]
Severe abnormalities in liver and renal function and blood counts; [+6]